This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
|Articles|February 15, 2003
- BioPharm International-02-01-2003
- Volume 16
- Issue 2
Virus Inactivation in the 1990s ? and into the 21st Century: Part 5: Disinfection
by Gail Sofer, BioReliance Both the process and the product strongly influence viral inactivation, and unknown or unspecified details ? such as variability in virus titers, measuring devices, calibrations, and protocols ? can all influence log reduction values. This article series covers what you need to know to fully understand the properties of the test article, the viruses inactivated, and the critical control parameters for selected inactivation methods.
Advertisement
Articles in this issue
over 23 years ago
Becoming a Partner of Choice and Evaluating Prospective Alliancesover 23 years ago
Guest Editorial: Maybe You Need a Corporate Marriage Counselorover 23 years ago
Inside Washington: AIDS Prevention Campaign Spotlights Biotechover 23 years ago
Survival Strategies: Keeping Tabs on Trainingover 23 years ago
Outsourcing Outlook: Contract Services' Crystal BallAdvertisement
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Advertisement
Advertisement
Trending on BioPharm International
1
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
2
The BioPharm Brief: A Psoriatic Arthritis Approval, a Subcutaneous Fabry Bet, and ADC Capacity
3
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
4
FDA Approves Sun Pharma’s Ilumya for Active Psoriatic Arthritis
5